McKesson vs Moderna
McKesson (MCK), health care, and Moderna (MRNA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
McKesson is worth $127B on the stock market and Moderna $83.9B: McKesson is valued at 51% more. McKesson's operating margin in its latest fiscal year was 1.54% and Moderna's -158%. Over the past year McKesson's share price has moved +28.4% and Moderna's +764%.
Key facts
- McKesson market value
- $127B
- Moderna market value
- $83.9B
- McKesson P/E
- 28.4
- McKesson revenue
- $403.4BFY to 2026-03-31
- Moderna revenue
- $1.9BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | McKesson | Moderna |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2026-03-31 | 2025-12-31 |
| Size | ||
| Market cap | $127Bhigher | $83.9Blower |
| Revenue | $403.4Bhigher | $1.9Blower |
| Earnings | $4.8Bhigher | -$2.8Blower |
| Employees | 41,600higher | 4,700lower |
| Total assets | $82.3Bhigher | $12.3Blower |
| Valuation | ||
| P/E | 28.4 | — |
| P/S | 0.3lower | 43.2higher |
| P/B | — | 12.3 |
| Dividend yield | 0.31%higher | 0.00%lower |
| Profitability | ||
| Operating margin | 1.54%higher | -158%lower |
| Balance sheet | ||
| Net assets | -$2.2Blower | $8.7Bhigher |
| Total liabilities | $83.2Bhigher | $3.7Blower |
| Total debt | $6.5Bhigher | $590Mlower |
| Cash on hand | $4Bhigher | $2.6Blower |
| Price change | ||
| Today | -0.48%higher | -3.65%lower |
| 1 year | +28.4%lower | +764%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
McKesson only (13)
- Ron Muhlenkamp (founder)5.7%
- Charles Brandes (founder)0.8%
- Frank Sands0.6%
- Paul Tudor Jones0.4%
- Stephen Mandel0.3%
- Cliff Asness0.2%
- Jim Simons (1938–2024)0.2%
- David Shaw (founder)0.2%
- Ray Dalio (founder)0.2%
- Ken Griffin0.2%
- Joel Greenblatt0.1%
- Howard Gleicher<0.1%
- Temasek<0.1%
Moderna only (2)
- Baillie Gifford team2.1%
- Ron Baron0.4%
Percentages are each holding's share of that investor's reported portfolio. Who owns MCK · Who owns MRNA
More on McKesson
Further comparisons
McKesson against its closest peers
Moderna against its closest peers
Learn
Questions and answers
Which is bigger, McKesson or Moderna?
By market value, McKesson is the larger: $127B against $83.9B for Moderna. By revenue in its latest fiscal year, McKesson is the larger: $403.4B against $1.9B for Moderna.
Which has the higher operating margin?
McKesson: 1.54%, against -158% for Moderna. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
McKesson: 0.31%, against 0.00% for Moderna. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
McKesson: $6.5B, against $590M for Moderna. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both McKesson and Moderna?
None of the tracked superinvestors holds both in their latest 13F filing. 13 hold McKesson and 2 hold Moderna.
Cite this page
Funkfolio, “McKesson vs Moderna”, data as of 17 November 2026. https://funkfolio.com/compare/mck-vs-mrna
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.